Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
The Left Atrium

Rethinking randomized controlled trials

Jeremy Howick
CMAJ November 18, 2008 179 (11) 1178; DOI: https://doi.org/10.1503/cmaj.081675
Jeremy Howick PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2008 Canadian Medical Association

Randomized Controlled Trials: Questions, Answers and Musings, second edition Alejandro R. Jadad, Murray W. Enkin; BMJ Books/Blackwell Publishing; 2007; 160 pp $35.95 ISBN 978-1-4051-3266-4

When Randomized Controlled Trials was first published in 1998, it was hailed in a BMJ review as a complete, concise and clearly written guide. Almost a decade later, the disappointing results of efforts to improve the reporting and conduct of clinical trials1 suggest that a succinct description of the randomized controlled trial that is free from unnecessary jargon remains useful.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Photo by: BMJ Books/Blackwell Publishing

The updated edition surpasses the first edition as a lucid and readable description of randomized controlled trials in several ways. For example, the table of contents fits neatly onto a page, compared to the unnecessarily complex 3-page table of contents in the first edition, while the discussion of bias is better organized.

The new edition, however, is much more than a tidied-up version of the original. The new book is co-authored by Murray Enkin (who played a major editorial role in the first edition), a long-standing colleague and collaborator of Alejandro Jadad. The latest edition also dedicates a chapter to the ethics of clinical trials.

The most important innovation, however, is that that the new book endorses a new attitude toward randomized controlled trials. Although the authors “were, and are, strong and enthusiastic proponents of RCTs” (p. 44), they caution against the uncritical view that randomized controlled trials provide the best answers to all medical problems. The authors' revised views are expounded mostly in new sections entitled “Musings” at the end of each chapter.

Jadad and Enkin's new outlook on randomized controlled trials stems partly from their argument that since there is a “practically infinite” number of possible biases, no randomized controlled trial will deliver results that are absolutely bias-free. They admonish us to stop worshipping the randomized controlled trial as if it were a talisman that would guarantee objectivity. Yet one could object that this problem could be overcome to a large extent if we were much better at conducting randomized controlled trials, for example, if we blinded all of the groups involved in a trial. Jadad and Enkin, however, contend that there is a deeper problem. Although (they argue) the randomized controlled trial is useful for simple problems (how to treat pneumococcal pneumonia), as well as complicated problems (how to anesthetize a patient for chest surgery), it has limited use for the increasingly complex problems faced by the medical community today. Factors that add complexity range from the effects of patient preference on outcomes and the effects of being enrolled in a trial to the qualitative aspects of health care.

They advocate a more critical stance and a multidisciplinary approach to solving complex problems. More specifically, Jadad and Enkin recommend nontraditional randomized controlled trials (such as the patient preference design), qualitative research, increased democratization of the research process, evaluation of research by independent bodies and even investigation of the rhetorical aspects of trials.

However, the authors' claim that complex problems cannot be solved by randomized controlled trials, although intuitively plausible, lacks sufficient motivation. The authors' cite 2 examples of complex problems — raising a child and treating dementia — where randomized controlled trials have limited use. Yet raising a child is not a medical problem, while it would seem that randomized controlled trials would be a good way to evaluate a pharmacological intervention for dementia. One looks forward to a third edition, or indeed a separate book, where the authors bring their expertise and clear expository style to bear on a description of the alternatives to randomized controlled trials and more extensive justifications for why we need these other methods.

Lastly, the short section on “equivalence” trials might be expanded to explain the often-confused difference between noninferiority, superiority and equivalence trials. These distinctions bear on the practical and ethical problems (that the authors mention in their chapter on ethics) surrounding the use of placebo-controlled trials where there is an established treatment.

Overall, this book succeeds in providing a remarkably clear and readable description of the randomized trial. Anyone interested in a highly accessible description of randomized trials, whilst enjoying a good read, will acquire their personal copy.

REFERENCE

  1. 1.↵
    Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006;185:263-7.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 179 (11)
CMAJ
Vol. 179, Issue 11
18 Nov 2008
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rethinking randomized controlled trials
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rethinking randomized controlled trials
Jeremy Howick
CMAJ Nov 2008, 179 (11) 1178; DOI: 10.1503/cmaj.081675

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Rethinking randomized controlled trials
Jeremy Howick
CMAJ Nov 2008, 179 (11) 1178; DOI: 10.1503/cmaj.081675
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCE
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • On becoming
  • Chronicles of a cardiologist in Canada's North
Show more The Left Atrium

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire